Here’s a classic small-cap biotech story with a twist: instead of betting everything on a single, risky drug candidate in development, a company is buying a portfolio of products that are already being used by doctors and paid for by insurance. NexGel Inc. (NXGL) announced on Tuesday it has agreed to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity, Inc. (CELU), a regenerative and cellular medicine company.
NexGel is calling this the most significant milestone in its history, and the numbers back up the hype. The company says the deal is expected to nearly triple its annual revenue to about $35 million in 2026. More importantly, it expects to become profitable immediately. For a small medical technology player, that’s a game-changer—shifting from a story about potential to a story about proven, commercial-scale products.
So, what exactly is NexGel buying? The portfolio encompasses regenerative biomaterial products and technologies focused on practical, in-demand areas: tendon repair, skin grafts, and bone growth. These aren’t science experiments; the products carry over a decade of clinical use, have demonstrated clinical utility, and, crucially, have existing insurance reimbursement pathways. That last part is often the hardest hurdle for new medical products to clear, and it means these products come with a built-in, stable revenue base.
The transaction adds six commercial-stage products. On top of that, NexGel has plans for three additional 510(k) regulatory filings in 2026, 2027, and 2028, offering a visible pipeline for future portfolio growth. The company also sees opportunities to scale its own complementary biomaterials and hydrogel technologies across the newly acquired product sectors, potentially expanding sales further.
Of course, a deal like this requires capital. In connection with the transaction and a previously announced approximate $1.8 million financing, NexGel expects to close on approximately $14.9 million in additional financing during the first quarter or early in the second quarter of 2026. This financing was initially announced in February relating to a potential acquisition targeted for Q1 2026, subject to the completion of due diligence.
The news follows other strategic moves by NexGel. In December 2025, the company's previously announced spin-off of select drug delivery application assets received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings.
The market reacted positively to the news. NexGel shares were up 6.19% at $1.19 during premarket trading on Tuesday, according to market data.
